Polaryx Therapeutics, Inc. (PLYX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.80
- As of
Kresmion compiles this page from PLYX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Polaryx Therapeutics, Inc. (PLYX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
See the full PLYX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PLYX on one page. Preview it with sample data, then open it live with a free account.
Preview the PLYX dossierActive events for PLYX
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in PLYX
FREE, NO ACCOUNT
Every event on PLYX, as it fires
New filings, 13F moves and cross asset events on PLYX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, PLYX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
Going concern statement
PLYX's 10-Q filed Aug 13, 2026 states:
These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on PLYX
PLYX against its peers
PLYX's return on equity of -196.8% ranks in the 30th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | PLYX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 3.6M | n/a | 11 |
| Operating margin | n/a | -1449.7% | n/a | 10 |
| Net margin | n/a | -1046.4% | n/a | 11 |
| Return on equity | -196.8% | -87.6% | 30 | 14 |
Peers (21): GNLX, KZIA, TNYA, RLYB, ATRA, NRXS, CBUS, BETRF, NTHI, OKYO, ICCC, TVGN, VANI, CING, VXRT, PMVP, MIST, ACRV, BDTX, CRDF, SMNR. Left out: TLSA (period gap), TNXP (no annual filing), RTSN (no annual filing), CNXU (no annual filing). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PLYX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PLYX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PLYX in the last 180 days.
Upstream: SEC EDGAR filings for PLYX
Kresmion, "Polaryx Therapeutics, Inc. (PLYX) institutional holdings and SEC filings", data as of 2026-09-14, https://kresmion.com/research/PLYX. Upstream data: SEC EDGAR filings for PLYX.
Link to this data (HTML):
<a href="https://kresmion.com/research/PLYX">Polaryx Therapeutics, Inc. (PLYX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PLYX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PLYX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.